Endeavor

Shahram is Founder and General Partner at Civilization Ventures, a venture capital firm focused on supporting cutting edge innovations in health tech and biology. Prior to founding Civilization Ventures, Shahram was an entrepreneur and angel investor. Shahram is a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in- class therapeutics for cancer, now in Phase 1 clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics big data analytics pioneer acquired by Illumina in 2013. Shahram is also a seed investor in category-defining startups such as Omada Health and Counsyl. Shahram began his career in Silicon Valley as startup counsel at Wilson Sonsini Goodrich & Rosati, and later as a high tech investment banker at Goldman Sachs. Shahram earned his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and obtained a BA in Economics from Pomona College. Vivek Garipalli is the co-founder and CEO of Clover Health, a health insurance company leveraging data to proactively improve health outcomes, filling gaps in care and reducing avoidable costs. Prior to founding Clover, Vivek founded CarePoint Health, a fully integrated healthcare system in New Jersey. Through his role at CarePoint – whose mission is to serve uninsured and underinsured patient populations – Vivek experienced the misalignment of providers and insurance companies first-hand. Prior to CarePoint, Vivek owned and operated various outpatient facilities. He began his career in finance, holding roles at Credit Suisse First Boston, J.P. Morgan Partners and Blackstone Group. Vivek is active in health tech, serving as a board member of Flatiron Health and Doctor Evidence. He earned an undergraduate degree in business administration at Emory University with a concentration in entrepreneurship. Born and raised in Brazil, Dr. Fred Aslan is the founder of Adavium Medical (previously known as ADVANCE Medical). He is also affiliated with Venrock, a leading Silicon Valley venture capital firm he joined in 2006. While a full-time investor at Venrock prior to founding Adavium, Dr. Aslan was a co- founder and board member of Receptos Pharmaceuticals, a NASDAQ-listed biotech company, which was subsequently acquired by Celgene for more than $8 billion. He also led Venrock's investment in Zeltiq, a NASDAQ-listed medical device company that was valued at more than $1 billion. Prior to Venrock, he was Director of Business Development and led Investor Relations at CuraGen, a NASDAQ-listed oncology- focused biotech company, and was a strategy consultant with Boston Consulting Group (BCG). He was named the "2014 Business Professional of the Year" by the Brazilian government. He is also a board member of Femasys, a US-based women's health medical device company, and BayBrazil, a Silicon Valley- based not-for-profit organization promoting ties between Silicon Valley and Brazil. Dr. Aslan received a B.S. in Biology from Duke University, an M.D. from Yale and an M.B.A. from Harvard. CIVILIZATION VENTURES Shahram Seyedin-Noor Founder & General Partner CLOVER Vivek Garipalli Cofounder & CEO VENROCK / ADAVIUM MEDICAL Fred Aslan, MD Vice President / Founder & CEO

• Cover